Pharma Focus Europe

Senores Pharmaceuticals, Inc. Introduces Nicardipine Hydrochloride Capsules USP, Available in 20 Mg and 30 Mg, to the U.S. Market.

Tuesday, September 26, 2023

Senores Pharmaceuticals, Inc. has recently introduced Nicardipine Hydrochloride Capsules USP in 20 mg and 30 mg strengths to the U.S. market. These capsules are equivalent in terms of both bioequivalence and therapeutic effect to Chiesi USA, Inc.'s Cardene Capsules in the same strengths. The marketing of this product will be handled by Burel Pharmaceuticals, LLC.

Nicardipine Hydrochloride Capsules USP serve two primary purposes: managing chronic stable angina (effort-associated angina) and treating hypertension.
Senores Pharmaceuticals, Inc. has received a Competitive Generic Therapy (CGT) designation for Nicardipine Hydrochloride Capsules USP in 20 mg and 30 mg doses. As a result, the company is entitled to a 180-day period of CGT exclusivity upon the commencement of commercial marketing.

Dhananjay Barot, Director of Senores Pharmaceuticals, Inc., expressed their satisfaction with the launch of Nicardipine Hydrochloride Capsules in the U.S. market through their marketing partner. He emphasized the company's commitment to improving healthcare. Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, shared this vision for a healthier future and highlighted their ever-expanding product portfolio.

Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024